ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby publishes the memorandum for the Initial Public Offering which the company plans to commence on June 8, 2016, in connection with the planned listing on Nasdaq Stockholm First North. The subscription period runs until June 22, 2016.

The Memorandum, which as of today is available in Swedish at the company’s (www.expres2ionbio.com) and Sedermera Fondkommission’s (www.sedermera.se) respective websites, contains a complete description of the company and its activities, the complete terms and instructions for the planned Initial Public Offering as well as a description of the risks that potential investors should consider along with the company’s growth opportunities. Teaser and subscription form will be published at the company’s and Sedermeras Fondscommision’s respective websites, when the subscription period commences.

Read the whole press release (pdf)